Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Previous winners, 2012–2022

2022 winners
Alexandre Fagnan
Junior Research Grant 2022
Deciphering the chromatin remodeling mechanism mediated by GATA2 ZnF1 mutations in AML

Samuele Ferrari
Junior Research Grant 2022
Innovative targeted base editing strategies for gene correction of WHIM syndrome

Lars Velten
Advanced Research Grant 2022
The role of the DNA methylation…

Read more

SWG Grant-funded projects, 2024

In November and December of 2023, SWGs were invited to develop project ideas and apply for a 2024 SWG Grant. ApplicationsWe received 11 different applications from 9 SWGs. This was two more applications than we received in 2022.

Read more

Highlights from the SWG

Impactful activitiesSymposium at EHA2023The SWG held a symposium on ‘2. 0 diagnostics in hematology: the role of AI’ at the EHA2023 Congress. EHA2023 took place from June 8–11, 2023, in Frankfurt, Germany.

Read more

EHA Research Conference 2022

Dates: October 17-20, 2022
Location: Palermo (Sicily), Italy
Chairs: Emmanuelle Passegué, Cristina Lo Celso, Mick Milsom, Meri Alberich Jorda, Antonella Fidanza, Jürg Schwaller, Thomas Mercher and Brian Huntly

Registration is closed

EHA is proud to announce the inaugural edition of the EHA Research Conference,…

Read more